NR4A1 and breast cancer: Indeed, data from the NAFTA trial (North American Fareston versus Tamoxifen Adjuvant) trial [4], which included 1813 postmenopausal women with hormone receptor-positive invasive BC, and the International Breast Cancer Study Group Trial 10-93 [5], have shown that omitting axillary evaluation does not affect overall survival or locoregional recurrence in women with early-stage disease [3].